Semaglutide Shows 3–5 Year Slowdown in Biological Aging in a 2025 Trial

In a 32-week, randomized trial of 108 adults with HIV-associated lipohypertrophy, weekly semaglutide reduced biological age by about 3.1 years on multiple epigenetic clocks and up to 5 years on the most sensitive ones, with DunedinPACE slowing by ~9%. The biomarker shifts correlated with reductions in inflammation and visceral fat, suggesting aging slows via metabolic effects rather than a direct anti-aging action. Limitations include population specificity and reliance on epigenetic biomarkers; broader trials are needed to determine applicability to the general population and real-world health outcomes.